Tango Therapeutics is using the principle of synthetic lethality to develop medicines for cancer patients. Synthetic lethality describes a situation where loss of two targets results in cell death, while loss of either one alone does not. Since some tumors already possess target loss, Tango is using their CRISPR-based functional genomics target discovery platform and analytic pipeline to identify novel synthetic lethal targets that can selectively kill tumor cells. Tango is applying this approach in two core areas:  tumor suppressor gene loss and  immune evasion. Once targets are identified, Tango screens for drugs that have therapeutic potential. Tango’s lead candidate, TNG908, is being evaluated in clinical trials for MTAP-deleted tumors.